See more : TINC NV (0R7T.L) Income Statement Analysis – Financial Results
Complete financial analysis of Gentian Diagnostics ASA (GENT.OL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gentian Diagnostics ASA, a leading company in the Medical – Devices industry within the Healthcare sector.
- Cirata plc (WANSF) Income Statement Analysis – Financial Results
- Air New Zealand Limited (AIZ.AX) Income Statement Analysis – Financial Results
- Corticeira Amorim, S.G.P.S., S.A. (COR.LS) Income Statement Analysis – Financial Results
- Keysheen (Cayman) Holdings Co., Limited (8427.TW) Income Statement Analysis – Financial Results
- Knight Club Capital Asset Management Public Company Limited (KCC.BK) Income Statement Analysis – Financial Results
Gentian Diagnostics ASA (GENT.OL)
About Gentian Diagnostics ASA
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 136.19M | 101.64M | 83.12M | 68.37M | 47.95M | 46.11M | 34.99M | 30.90M | 25.59M | 24.55M | 22.89M |
| Cost of Revenue | 66.75M | 52.64M | 43.18M | 32.59M | 25.45M | 6.59M | 5.79M | 7.02M | 4.95M | 5.01M | 5.12M |
| Gross Profit | 69.44M | 49.00M | 39.95M | 35.78M | 22.50M | 39.52M | 29.20M | 23.88M | 20.64M | 19.54M | 17.78M |
| Gross Profit Ratio | 50.99% | 48.21% | 48.06% | 52.34% | 46.93% | 85.71% | 83.46% | 77.29% | 80.67% | 79.59% | 77.64% |
| Research & Development | 0.00 | 24.69M | 26.81M | 26.12M | 19.21M | 3.80M | 3.94M | 2.15M | 3.00M | 3.47M | 2.25M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.42M | 5.96M | 5.23M | 194.62K | 174.29K | 132.55K |
| Selling & Marketing | 2.10M | 2.39M | 1.70M | 2.09M | 2.01M | 1.58M | 831.98K | 724.30K | 565.33K | 394.64K | 419.21K |
| SG&A | 2.10M | 2.39M | 1.70M | 2.09M | 2.01M | 1.58M | 831.98K | 724.30K | 759.94K | 568.93K | 551.75K |
| Other Expenses | 80.10M | 69.85M | 61.09M | 51.52M | 47.65M | 43.37M | 34.67M | 25.83M | 18.56M | 16.65M | 13.81M |
| Operating Expenses | 88.36M | 72.24M | 62.79M | 53.61M | 49.66M | 55.16M | 45.40M | 33.93M | 22.33M | 20.69M | 16.61M |
| Cost & Expenses | 148.96M | 124.87M | 105.97M | 86.19M | 75.11M | 61.75M | 51.19M | 40.95M | 27.28M | 25.70M | 21.73M |
| Interest Income | 2.67M | 1.11M | 85.00K | 599.00K | 2.00M | 700.52K | 860.90K | 485.04K | 95.89K | 31.68K | 94.80K |
| Interest Expense | 871.00K | 1.26M | 1.45M | 550.00K | 362.00K | 669.33K | 12.18K | 1.34M | 438.27K | 749.29K | 721.45K |
| Depreciation & Amortization | 6.49M | 6.36M | 4.96M | 4.40M | 6.13M | 3.90M | 3.02M | 2.30M | 1.22M | 860.21K | 488.50K |
| EBITDA | -3.01M | -15.94M | -18.38M | -12.52M | -21.02M | -15.77M | -12.10M | -6.62M | -1.56M | -1.30M | 1.47M |
| EBITDA Ratio | -2.21% | -11.92% | -20.98% | -16.37% | -40.07% | -14.55% | -34.61% | -21.44% | -6.12% | -5.29% | 9.10% |
| Operating Income | -12.76M | -23.24M | -22.85M | -17.82M | -27.15M | -20.69M | -16.20M | -10.06M | -1.89M | -1.14M | 1.17M |
| Operating Income Ratio | -9.37% | -22.86% | -27.49% | -26.07% | -56.63% | -44.86% | -46.30% | -32.55% | -7.39% | -4.66% | 5.09% |
| Total Other Income/Expenses | 2.40M | -383.00K | -1.95M | 355.00K | 1.45M | 951.33K | 1.06M | 1.13M | -1.33M | -1.76M | -292.08K |
| Income Before Tax | -10.37M | -23.62M | -24.79M | -17.47M | -39.79M | -19.73M | -15.14M | -8.93M | -3.22M | -2.91M | 873.99K |
| Income Before Tax Ratio | -7.61% | -23.24% | -29.83% | -25.55% | -82.99% | -42.80% | -43.26% | -28.89% | -12.59% | -11.85% | 3.82% |
| Income Tax Expense | 282.00K | 383.00K | 5.17M | -355.00K | 63.00K | 63.68K | 32.87K | 1.13M | -893.83K | -1.02M | 429.37K |
| Net Income | -10.65M | -24.00M | -24.79M | -17.11M | -39.86M | -19.80M | -15.17M | -8.93M | -3.22M | -2.91M | 873.99K |
| Net Income Ratio | -7.82% | -23.61% | -29.83% | -25.03% | -83.12% | -42.94% | -43.36% | -28.89% | -12.59% | -11.85% | 3.82% |
| EPS | -0.69 | -1.56 | -1.61 | -1.11 | -2.59 | -1.29 | -1.08 | -0.80 | -0.29 | -0.26 | 0.08 |
| EPS Diluted | -0.69 | -1.56 | -1.61 | -1.11 | -2.59 | -1.29 | -1.08 | -0.80 | -0.29 | -0.26 | 0.08 |
| Weighted Avg Shares Out | 15.42M | 15.42M | 15.42M | 15.41M | 15.40M | 15.40M | 14.00M | 11.14M | 11.14M | 11.14M | 11.14M |
| Weighted Avg Shares Out (Dil) | 15.42M | 15.42M | 15.42M | 15.41M | 15.40M | 15.40M | 14.00M | 11.14M | 11.14M | 11.14M | 11.14M |
Source: https://incomestatements.info
Category: Stock Reports